GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » La Jolla Pharmaceutical Co (NAS:LJPC) » Definitions » Cash from Discontinued Operating Activities

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Cash from Discontinued Operating Activities : $0.00 Mil (TTM As of Jun. 2022)


View and export this data going back to 1994. Start your Free Trial

What is La Jolla Pharmaceutical Co Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

La Jolla Pharmaceutical Co's Cash from Discontinued Operating Activities for the three months ended in Jun. 2022 was $0.00 Mil. It means La Jolla Pharmaceutical Co received $0.00 Mil from discontinued investing activities. La Jolla Pharmaceutical Co's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00 Mil.


La Jolla Pharmaceutical Co Cash from Discontinued Operating Activities Historical Data

The historical data trend for La Jolla Pharmaceutical Co's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

La Jolla Pharmaceutical Co Cash from Discontinued Operating Activities Chart

La Jolla Pharmaceutical Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash from Discontinued Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

La Jolla Pharmaceutical Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash from Discontinued Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

La Jolla Pharmaceutical Co Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


La Jolla Pharmaceutical Co Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of La Jolla Pharmaceutical Co's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description

Industry
Traded in Other Exchanges
N/A
Address
201 Jones Road, Suite 400, Waltham, MA, USA, 02451
La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
Executives
Larry G. Edwards director, officer: Chief Executive Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Michael S Hearne officer: Chief Financial Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Robert Rosen director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Kevin C Tang director, 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Darryl Wellinghoff officer: Chief Commercial Officer 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Lakhmir S Chawla officer: Chief Medical Officer 1960 KIRBY ROAD, MCLEAN VA 22101
Jennifer Carver officer: Sr. Vice President, Operations 725 NEWPORT STREET, DENVER CO 80220
James Rolke officer: Chief Scientific Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
George F Tidmarsh director, officer: President, CEO & Secretary

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Headlines

From GuruFocus